Physician profile
Karah L Brashier
NPI 1497096101
$566,905.72
in general payments reported to CMS, 2019-2025
36 companies · $198K in 2025
The $198K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $33K · 2022: $40K · 2023: $126K · 2024: $170K · 2025: $198K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $276K · Honoraria: $97K · Travel and Lodging: $71K · Consulting Fee: $29K · Food and Beverage: $21K · Education: $61.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $276,298.00 |
| Honoraria | $97,342.00 |
| Travel and Lodging | $70,746.15 |
| Consulting Fee | $29,060.00 |
| Food and Beverage | $20,688.82 |
| Education | $61.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $279,434.00 | 2021-2025 | |
| Axsome Therapeutics, INC. | $135,397.56 | 2023-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $105,174.56 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25,250.52 | 2021-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $6,262.41 | 2021-2024 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $2,998.20 | 2021-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Allergan, INC. | $2,603.78 | 2021 | |
| Alkermes, INC. | $1,756.78 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| E.R. Squibb & Sons, L.L.C. | $1,089.66 | 2025 | Cobenfy |
| Tris Pharma INC | $1,003.29 | 2021-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Corium, LLC | $834.72 | 2021-2025 | Azstarys, Azstarys |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $704.59 | 2021-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $556.25 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $547.39 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Supernus Pharmaceuticals, INC. | $517.11 | 2021-2025 | Qelbree, Qelbree |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $509.71 | 2021-2022 | |
| Lundbeck LLC | $472.16 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $331.74 | 2021-2025 | Trintellix |
| Avanir Pharmaceuticals, INC. | $315.10 | 2021-2022 | |
| Eisai INC. | $166.85 | 2021 | |
| Noven Therapeutics, LLC | $121.28 | 2023-2025 | Xelstrym, Secuado |
| Astrazeneca Pharmaceuticals Lp | $120.16 | 2021 | |
| Bausch Health US, LLC | $116.78 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $96.66 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $81.53 | 2024 | Spravato |
| Neos Therapeutics, Lp | $70.45 | 2021-2025 | Adzenys Xr-Odt |
| Idorsia Pharmaceuticals US INC | $68.68 | 2022-2023 | Quviviq |
| Merck Sharp & Dohme LLC | $59.31 | 2021-2023 | Belsomra |
| Vanda Pharmaceuticals INC. | $55.15 | 2025 | Fanapt, Hetlioz |
| Adlon Therapeutics L.P. | $37.06 | 2021 | |
| Collegium Pharmaceutical, INC. | $35.18 | 2025 | Jornay Pm |
| Almatica Pharma LLC | $32.64 | 2022-2024 | Loreev Xr |
| Arbor Pharmaceuticals, INC. | $29.09 | 2021-2022 | |
| Indivior INC. | $27.42 | 2023 | Perseris |
| Sage Therapeutics, LLC | $15.52 | 2025 | Zurzuvae |
| Janssen Biotech, INC. | $12.43 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karah Brashier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.